Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.57 |
| ▸ | ITGB6 | P18564 | 8/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.48 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.46 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20141252 | 0.79 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL31075798 | 0.77 | ITGAV (0.49) | ITGAVITGB3ITGB6ITGB5ITGA5 | |
| SCHEMBL31075661 | 0.77 | ITGAV (0.49) | ITGAVITGB3ITGB6ITGB5ITGA5 | |
| SCHEMBL31075922 | 0.77 | ITGAV (0.49) | ITGAVITGB3ITGB6ITGB5ITGA5 | |
| SCHEMBL30306767 | 0.77 | SLC6A2 (0.52) | — | |
| SCHEMBL31076035 | 0.76 | ITGAV (0.50) | ITGAVITGB3ITGB6ITGB5ITGA5 | |
| SCHEMBL31075950 | 0.76 | ITGAV (0.50) | ITGAVITGB3ITGB6ITGB5ITGA5 | |
| SCHEMBL23341168 | 0.76 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL30802369 | 0.76 | SLC6A2 (0.52) | — | |
| SCHEMBL31075931 | 0.75 | ITGAV (0.48) | ITGAVITGB3ITGB6ITGB5ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173572-A1 | INHIBITING α vβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |